Today, Servier Pharmaceutics acquired the worldwide rights to BN104, a potential best-in-class precision therapy for AML and ALL, from BioNova Pharmaceuticals.
BioNova today announced that Center of Drug Evaluation (CDE) had approved its investigational new drug (IND) application for BN104 for the treatment of relapsed/refractory (R/R) acute leukemia in China. Continue Reading
BioNova announces 乐舒克® (Belumosudil Mesylate Tablets) has been approved by the China NMPA for the treatment of patients with cGVHD who have an inadequate response to corticosteroids or other systemic treatments.
BioNova Pharmaceuticals Limited (BioNova), a company
dedicated to the discovery, development and commercialization of innovative medicines for the
treatment of diseases with unmet medical needs, today announced that the U.S. Food and
Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to BN104 for the
treatment of acute myeloid leukemia (AML).
BioNova Pharmaceuticals Limited (BioNova), a company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, today announced that the first patient has been dosed in the phase 1 clinical study…
